Wikipedia

Volixibat

Volixibat (INN;[1] development code SHP626) is a medication under development as a possible treatment for nonalcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD). No other pharmacotherapy yet exists for NASH, so there is interest in whether volixibat can prove to be both safe and effective. To encourage development and testing, the U.S. Food and Drug Administration (FDA) has issued fast track status.[2]

Volixibat
Clinical data
Other namesN-(3-O-Benzyl-6-O-sulfo-β-D-glucopyranosyl)-N′-{3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxo-2,3,4,5-tetrahydro-1H-1λ6-benzothiepin-5-yl]phenyl}urea; SHP626
Routes of
administration		By mouth
Legal status
Legal status
  • Investigational
Identifiers
  • 3-O-Benzyl-N-({3-[(3S,4R,5R)-3-butyl-7-(dimethylamino)-3-ethyl-4-hydroxy-1,1-dioxido-2,3,4,5-tetrahydro-1-benzothiepin-5-yl]phenyl}carbamoyl)-6-O-sulfo-β-D-glucopyranosylamine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC38H51N3O12S2
Molar mass805.96 g·mol−1
3D model (JSmol)
  • CCCC[C@]1(CC)CS(=O)(=O)c2ccc(cc2[C@H]([C@H]1O)c3cccc(NC(=O)N[C@@H]4O[C@H](COS(=O)(=O)O)[C@@H](O)[C@H](OCc5ccccc5)[C@H]4O)c3)N(C)C
  • InChI=1S/C38H51N3O12S2/c1-5-7-18-38(6-2)23-54(46,47)30-17-16-27(41(3)4)20-28(30)31(35(38)44)25-14-11-15-26(19-25)39-37(45)40-36-33(43)34(51-21-24-12-9-8-10-13-24)32(42)29(53-36)22-52-55(48,49)50/h8-17,19-20,29,31-36,42-44H,5-7,18,21-23H2,1-4H3,(H2,39,40,45)(H,48,49,50)/t29-,31-,32-,33-,34+,35-,36-,38-/m1/s1
  • Key:ULVBLFBUTQMAGZ-RTNCXNSASA-N

Volixibat is an IBAT inhibitor, meaning that it blocks the function of the IBAT protein (ileal bile acid transporter), which is also called SLC10A2 (solute carrier family 10 member 2) or ASBT (apical sodium–bile acid transporter). IBAT is most highly expressed in the ileum, where it is found on the brush border membrane of enterocytes. It is responsible for the initial uptake of bile acids, particularly conjugated bile acids, from the intestine as part of their enterohepatic circulation.[3]

References

edit
  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 75" (PDF). World Health Organization. p. 166. Retrieved 21 January 2017.
  2. ^ C D (August 3, 2016). "FDA Grants Fast Track Status to Volixibat". Internal Medicine News Digital Network. Frontline Medical Communications Inc., Parsippany, NJ, USA.
  3. ^ Dawson PA (2011). "Role of the intestinal bile acid transporters in bile acid and drug disposition". Drug Transporters. Handbook of Experimental Pharmacology. Vol. 201. pp. 169–203. doi:10.1007/978-3-642-14541-4_4. ISBN 978-3-642-14540-7. PMC 3249407. PMID 21103970.
 

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Volixibat&oldid=1211901751"